标题：Des-Gamma-Carboxy Prothrombin (DCP) Antagonizes the Effects of Gefitinib on Human Hepatocellular Carcinoma Cells
作者：Zhang, Yu-Sheng; Chu, Jia-Hui; Song, Zhi-Yu; Cui, Shu-Xiang; Qu, Xian-Jun
作者机构：[Zhang, Yu-Sheng; Chu, Jia-Hui; Song, Zhi-Yu; Qu, Xian-Jun] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Peoples R China.; [Cui, Shu-Xiang] Capi 更多
通讯作者地址：[Qu, XJ]Shandong Univ, Sch Pharmaceut Sci, 14 Wen Hua Xi Rd, Jinan 250012, Peoples R China.
来源：CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
关键词：Human hepatocellular carcinoma cells (HCC); Gefitinib; Chemotherapy;; Apoptosis resistance; Des-gamma-carboxy prothrombin (DCP); Antagonistic; effect
摘要：Background/Aims: Des-gamma-carboxy prothrombin (DCP), an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells, is known as a marker for HCC. Recent studies indicated that high levels of DCP are associated with the malignant potential of HCC. In this study, we aimed to investigate the association of DCP with gefitinib treatment failure in HCC and whether DCP counteracts gefitinib-induced growth inhibition and apoptosis of HCC. Methods: The experiments were performed in HCC cell lines HepG2 and PLC/PRF/5. The effects of gefitinib on HCC in the presence or absence of DCP were evaluated by the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide (MTT) assay. Apoptotic cells were identified by Annexin V-FITC/PI staining. Western blotting was performed to analyze the expressions of molecules related to the apoptotic caspase-dependent pathway and epidermal growth factor receptor (EGFR) pathway. Results: Gefitinib inhibited HCC cell proliferation and induced apoptosis in HCC cells. The effects of gefitinib on HCC cells were antagonized by DCP. In the presence of DCP, HCC cells were resistant to the gefitinib-induced inhibition of proliferation and stimulation of apoptosis. DCP prevented the activation of the apoptotic caspase-dependent pathway induced by gefitinib. These antagonistic effects of DCP also arose from its ability to up-regulate EGFR, c-Met and hepatocyte growth factor (HGF) in HCC cells. Conclusion: DCP antagonized gefitinib-induced HCC cell growth inhibition by counteracting apoptosis and up-regulating the EGFR pathway. High levels of DCP might thus lead to low response rates or possibly no response to gefitinib in patients with HCC. Copyright (C) 2015 S. Karger AG, Basel